Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?
Hye Lim Lee(Korea University Medical Center), Ha Young Shin(Yonsei University), Jin Myoung Seok(Samsung Medical Center), Byung‐Jo Kim(Korea University), Han-Wook Ryu, So‐Young Huh(Kosin University Gospel Hospital), Joong‐Yang Cho(Inje University Ilsan Paik Hospital), Jae Young Seong(Korea University), Jeeyoung Oh(Université Paris-Sud), Bong-Chul Kim(Korea University), Eun Bee Cho, Hung Youl Seok(Keimyung University), Sang-Soo Lee(Chungbuk National University), Ju‐Hong Min(Samsung Medical Center), Sa-Yoon Kang(Soonchunhyang University), Byoung Joon Kim(Samsung Medical Center), Oh-Hyun Kwon(Yonsei University)
Cited by 12
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284
Identification of Farnesyl Pyrophosphate and N-Arachidonylglycine as Endogenous Ligands for GPR92
|Journal of Biological Chemistry|2008|142
A New Subtype Classification of Ischemic Stroke Based on Treatment and Etiologic Mechanism
|European Neurology|2006|121
<i>GABBR2</i> mutations determine phenotype in rett syndrome and epileptic encephalopathy
|Annals of Neurology|2017|85